Genetic testing has been a game changer in cancer care and prevention, but could we be doing more? Could we use multigene panel testing more broadly to identify both more precise treatments and cancers earlier in patients and their family members?
In the study, “Multigene Panel Testing Yields High Rates of Clinically Actionable Variants Amongst a Large Colorectal Cancer Cohort,” presented at Digestive Disease Week 2022, we set out to better understand the potential yield of broadening genetic testing for hereditary cancer risk variants among patients diagnosed with colorectal cancer (CRC).